Neobook — clinical reference

ATC Code	R03BB04/R03BB06
Medicine	Long acting muscarinic antagonists (LAMA): Tiotropium, Glycopyrronium
Indication	Chronic Obstructive Pulmonary Disease (COPD)
NEMLC Recommendation	Not Approved
Review Indicators	Price
Date Ratified	14 December 2017

ATC Code	R03DC03
Medicine	Montelukast
Indication	Chronic management of severe uncontrolled asthma
NEMLC Recommendation	Approved for use in: - In adults (>12 years) with difficult to control asthma despite receiving high dose inhaled steroids and long-acting β₂ agonist, a trial of low dose sustained release theophylline should be tried before use of montelukast If there is no response to low dose theophylline, a 2-week trial of montelukast may be used - In children between 6 and 12 years of age with severe uncontrolled asthma despite being on high dose corticosteroids and long acting β₂ agonist, a 2-week trial of montelukast could be considered - In children less than 6 years with severe uncontrolled asthma on high dose inhaled corticosteroids, a 2-week trial of montelukast could be considered. If no benefit can be demonstrated after this period, montelukast should be discontinued
Review Indicators	Properly randomized efficacy and safety comparative studies of LTRA, low dose sustained release theophyllines and long acting β₂ agonist at all ages
Date Ratified	13 March 2008

Respiratory System